Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON - Seite 2

“Biotechs must walk a line between de-risking and validating their assets to instil confidence in potential investors while pursuing novel innovation to catch their interest. Ensuring there are robust clinical development strategies in place underpins both these goals. Support within the wider industry is available – partnering with large pharma and CROs will help biotechs continue to contribute to the innovative and scientific advancements of much needed medicines,” commented Chris Smyth.

There is still significant capital available for biotechs. In the whitepaper, “Optimising biotech funding”, ICON shares how companies can best position themselves to secure funding, as well as R&D strategies to maximise funding once it has been secured. Areas covered include:

• Considerations for biotechnology companies as they pursue funding from sources including venture capital firms and partnerships with large pharmaceutical companies
• How companies can make more strategic outsourcing decisions, participating in thoughtful collaborations to optimise their programs
• Best practices to optimise trial designs, maintain development timelines and build value into the program to maximise the impact of funding

For further information please visit www.ICONplc.com/biotech.

Ends

About the ICON Biotech Sector Survey

The survey, conducted on ICON’s behalf by Citeline in June 2023, included 133 respondents, predominantly located in Europe and North America from small pharmaceutical and biotech companies, mid-size pharmaceutical and biotech companies, and large biotech or venture capital organisations. The survey was designed to generate a more detailed picture of how biotechs are coping with cash constraints, the challenges encountered in the sector, and strategies to navigate the evolving landscape.

About ICON plc

ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,160 employees in 106 locations in 53 countries as at September 30, 2023. For further information about ICON, visit: www.iconplc.com.

ICON/ICLR-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20240108742855/en/

The Icon Stock at the time of publication of the news with a raise of +0,36 % to 248,4EUR on Tradegate stock exchange (08. Januar 2024, 09:33 Uhr).